MAP’s vision to accelerate patient access to medicines, devices and diagnostics is at the heart of everything we do.
An increasing number of clients were bringing orphan medicines to market and being referred for a Single Technology Appraisal instead of via the tailored Highly Specialised Technology route. There was limited coordination within the stakeholder community on this topic and a need to refresh the narrative on the case for change.
We established a Steering Group of supporting companies and developed an evidence-based report to make the case for change in rare diseases.
Our media campaign was launched resulting in one significant national news piece and six pharma sector news pieces.
Rolling engagement programme with 8 mentions in the UK Parliament of the report and its findings.
Parliamentary event with attendance of 13 charities and 8 Parliamentarians at Parliamentary roundtable.
Policy updates were provided for supporting companies.
Recognition by NICE of need for flexibilities in STA process and active reference of the need for interim recommendations in the draft NHS Commercial Framework.
Contributing new evidence helped to reset the narrative and provide a clear mandate that the NICE methods review could deliver change.
Greater focus on orphan medicines from groups such as the ABPI.
Copyright © 2021.
MAP BioPharma Limited.
All rights reserved.
MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
MAP BioPharma Limited is a registered company in England and Wales.
Company Registration Number 08209281
VAT Group Registration Number:
GB 292 8576 52